Interactive Research, Rehab Center for DBS Opening at Mount Sinai
People with Parkinson’s disease who undergo deep brain stimulation (DBS) at Mount Sinai in New York, along with…
Articles by Forest Ray PhD
Xadago as Add-on Therapy Eases Sleep Disturbances, Pilot Study Finds
Three months of Xadago (safinamide) as an add-on therapy lessened symptoms of rapid eye movement sleep behavior disorder (RBD)…
AbbVie Chooses Two Parkinson’s Therapies to Develop With Mission
AbbVie has selected two drug candidates — both targeting enzymes known as DUBs — for further development as possible…
CNM-Au8 Raises Cellular Energy in Brains of Patients in REPAIR-PD Trial
Clene Nanomedicine‘s investigational oral Parkinson’s treatment, CNM-Au8, safely and significantly increased energy metabolism in the brains of patients taking…
New Algorithm Groups Parkinson’s Symptoms to Predict Progression
Researchers with IBM and the Michael J. Fox Foundation developed a computational model that may help physicians better understand…
Six miRNAs in Blood Show Potential as Biomarkers
Six microRNAs may serve as biomarkers of Parkinson’s disease progression and early diagnosis, a recent study suggests. That study,…
Head Trauma, Lead Exposure Tied to Parkinson’s in Regional Study
Head trauma causing a person to black out, and lead exposure — even through hobbies — may more than double…
Adhera to Develop MLR-1019 for Easing Parkinson’s Symptoms
Adhera Therapeutics will develop MLR-1019 (armesocarb), a treatment candidate for easing Parkinson’s disease symptoms, following a licensing agreement with…
AC Immune Acquires Experimental Vaccine PD01, Other Therapies
Parkinson’s vaccine candidate Affitope PD01, along with maker Affiris’ portfolio of other alpha-synuclein-targeting therapies, was acquired by AC…
Hydrogel Device Hints at Better Option for Brain Stimulation
A flexible hydrogel-based device, implanted in the brains of mice, allowed scientists to stimulate and detect brain signals — in…